Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Recruiting Status: Active, not recruiting Age: 18 – 65 Years Old The first-in-human Phase 1/Phase 2a study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH). Learn More

The release as fetched from its publisher. adarx.com ↗